FGFR4 p.G388R signaling (WP5428)

Homo sapiens

Open in new tab Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
A germline variant, rs351855-G/A, in FGFR (c.1162G>A, p.Gly388Arg), activates the proximal STAT3 signaling pathway. This germline receptor variant, FGFR p.Gly388Arg, recruits STAT3 to inner cell membranes, resulting in increased levels of STAT3 tyrosine phosphorylation. This heritable variant-specific signaling pathway enhances both tumor-intrinsic proliferation and tumor-extrinsic immune evasion within the tumor microenvironment. The tumor-intrinsic molecular function is driven by elevated levels of tyrosine-phosphorylated STAT3 in tumor cells, promoting cell division and enhancing proliferation. Meanwhile, the tumor-extrinsic molecular function is influenced by increased levels of tyrosine-phosphorylated STAT3 in regulatory T cells and CD8 T cells. This activates the STAT3 signaling pathway predominantly in Tregs and alters the Treg/CD8 T cell ratio in lymphoid organs, thereby limiting immune surveillance within the tumor microenvironment.

Authors

Ulaganathan , Egon Willighagen , Kristina Hanspers , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Cell Type Ontology

malignant cell neoplastic cell effector CD8-positive, alpha-beta T cell regulatory T cell

Pathway Ontology

fibroblast growth factor signaling pathway cancer pathway

Participants
Query Drugst.One

Label Type Compact URI Comment
IL10 GeneProduct ensembl:ENSG00000136634
IL10 Protein uniprot:P22301
STAT3 Protein uniprot:P40763
CD334 Protein uniprot:P22455

References

  1. Interleukin-10 and the interleukin-10 receptor. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Annu Rev Immunol. 2001;19:683–765. PubMed Europe PMC Scholia
  2. Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. Shao H, Xu X, Mastrangelo MAA, Jing N, Cook RG, Legge GB, et al. J Biol Chem. 2004 Apr 30;279(18):18967–73. PubMed Europe PMC Scholia
  3. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Yu H, Kortylewski M, Pardoll D. Nat Rev Immunol. 2007 Jan;7(1):41–51. PubMed Europe PMC Scholia
  4. Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site. Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. Nature. 2015 Dec 24;528(7583):570–4. PubMed Europe PMC Scholia
  5. Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants. Ulaganathan VK, Ullrich A. Mol Cell Oncol. 2016 Feb 24;3(3):e1145176. PubMed Europe PMC Scholia
  6. STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. Kogan D, Grabner A, Yanucil C, Faul C, Ulaganathan VK. J Clin Invest. 2018 May 1;128(5):1867–72. PubMed Europe PMC Scholia
  7. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Raskov H, Orhan A, Christensen JP, Gögenur I. Br J Cancer. 2021 Jan;124(2):359–67. PubMed Europe PMC Scholia